Methods and implementation of a pediatric asthma pharmacogenomic study in the emergency department setting

被引:4
作者
Fishe, Jennifer N. [1 ]
Higley, Rebecca K. [1 ]
Casey, Deirdre [2 ]
Hogans, Lamont [2 ]
Wylie, Todd W. [1 ]
Hendry, Phyllis L. [1 ]
Henson, Morgan [1 ]
Bertrand, Andrew [1 ]
Blake, Kathryn V. [3 ]
机构
[1] Univ Florida, Coll Med Jacksonville, Div Res, Dept Emergency Med, 655 W 8th St, Jacksonville, FL 32209 USA
[2] Univ Florida Hlth Jacksonville, Jacksonville, FL USA
[3] Nemours Ctr Pharmacogen & Translat Res, Jacksonville, FL USA
关键词
asthma; bronchodilator response; emergency department; pediatric; pharmacogenomics; ASSOCIATION; ALBUTEROL; MEDICINE; CHILDREN;
D O I
10.1097/FPC.0000000000000414
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives The emergency department (ED) is a challenging setting to conduct pharmacogenomic studies and integrate that data into fast-paced and potentially life-saving treatment decisions. Therefore, our objective is to present the methods and feasibility of a pilot pharmacogenomic study set in the ED that measured pediatric bronchodilator response (BDR) during acute asthma exacerbations. Methods This is an exploratory pilot study that collected buccal swabs for DNA and measured BDR during ED encounters for pediatric asthma exacerbations. We evaluated the study's feasibility with a qualitative analysis of ED provider surveys and quantitatively by the proportion of eligible patients enrolled. Results We enrolled 59 out of 90 patients (65%) that were identified and considered eligible during a 5-month period (target enrollment 60 patients over 12 months). The median patient age was 7 years (interquartile range 4-9 years), 61% (N = 36) were male, and 92% (N = 54) were African American. Quality DNA collection was successful for all 59 patients. The ED provider survey response rate was 100%. Most ED providers reported that the study did not impact their workflow (98% of physicians, 88% of nurses, and 90% of respiratory therapists). ED providers did report difficulties with spirometry in the younger age group. Conclusions Pharmacogenomic studies can be conducted in the ED setting, and enroll a younger patient population with a high proportion of minority participants. By disseminating this study's methods and feasibility analysis, we aim to increase interest in pharmacogenomic studies set in the ED and aimed toward future ED-based pharmacogenomic decision-making.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 27 条
[1]  
Agarwal Dipti, 2007, Ann Thorac Med, V2, P103, DOI 10.4103/1817-1737.33697
[2]  
Akimbami L, 2015, ASTHMA PREVALENCE HL
[3]  
Akinbami Lara J, 2011, NCHS Data Brief, P1
[4]   Status of Childhood Asthma in the United States, 1980-2007 [J].
Akinbami, Lara J. ;
Moorman, Jeanne E. ;
Garbe, Paul L. ;
Sondik, Edward J. .
PEDIATRICS, 2009, 123 :S131-S145
[5]  
[Anonymous], 2013, Asthma facts-CDC's national asthma control program grantees
[6]  
[Anonymous], 2017, 2015 National Health Interview Survey (NHIS)
[7]   Towards precision medicine [J].
Ashley, Euan A. .
NATURE REVIEWS GENETICS, 2016, 17 (09) :507-522
[8]  
Ayuk AC, 2017, CLIN MED INSIGHTS-PE, V11, DOI 10.1177/1179556517720675
[9]   Population Pharmacodynamic Model of Bronchodilator Response to Inhaled Albuterol in Children and Adults With Asthma [J].
Blake, Kathryn ;
Madabushi, Rajanikanth ;
Derendorf, Hartmut ;
Lima, John .
CHEST, 2008, 134 (05) :981-989
[10]  
Bochud M, 2017, SWISS MED WKLY, V147, pw14528